These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 20222811)

  • 21. Less benefit from warfarin in diabetics after myocardial infarction?
    Smith PJ; Hurlen M; Abdelnoor M; Arnesen H
    Cardiology; 2008; 111(3):161-6. PubMed ID: 18434719
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Atrial fibrillation and thromboembolic events prevention. State of the art].
    Matteoli S; Trappolini M; Chillotti FM
    Minerva Cardioangiol; 2001 Feb; 49(1):1-13. PubMed ID: 11279381
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antithrombotic and thrombolytic therapy for ischemic stroke.
    Ocava LC; Singh M; Malhotra S; Rosenbaum DM
    Clin Geriatr Med; 2006 Feb; 22(1):135-54, ix-x. PubMed ID: 16377471
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antiplatelet therapy: anti-ischemic benefits versus bleeding risk.
    Gibson CM
    J Interv Cardiol; 2008 Dec; 21 Suppl 1():S3-9. PubMed ID: 19090934
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Antithrombotic therapy of acute coronary syndromes].
    Hölschermann H
    Hamostaseologie; 2007 Dec; 27(5):319-25; quiz 326-7. PubMed ID: 18060240
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The medical management of acute coronary syndromes and potential roles for new antithrombotic agents.
    Pollack CV; Goldberg AD
    J Emerg Med; 2008 May; 34(4):417-28. PubMed ID: 18226874
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Temporal trends in antiplatelet/antithrombotic use in acute coronary syndromes and in-hospital major bleeding complications.
    Motivala AA; Tamhane U; Saab F; Li J; Rogers EK; Froehlich J; Moscucci M; Eagle KA; Gurm HS
    Am J Cardiol; 2007 Nov; 100(9):1359-63. PubMed ID: 17950790
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Future developments in thrombolytic therapy].
    Bode C; Runge MS
    Z Kardiol; 1993; 82 Suppl 2():187-90. PubMed ID: 8328201
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antithrombotic therapy with fondaparinux in relation to interventional management strategy in patients with ST- and non-ST-segment elevation acute coronary syndromes: an individual patient-level combined analysis of the Fifth and Sixth Organization to Assess Strategies in Ischemic Syndromes (OASIS 5 and 6) randomized trials.
    Mehta SR; Boden WE; Eikelboom JW; Flather M; Steg PG; Avezum A; Afzal R; Piegas LS; Faxon DP; Widimsky P; Budaj A; Chrolavicius S; Rupprecht HJ; Jolly S; Granger CB; Fox KA; Bassand JP; Yusuf S;
    Circulation; 2008 Nov; 118(20):2038-46. PubMed ID: 18955665
    [TBL] [Abstract][Full Text] [Related]  

  • 30. What an interventional cardiologist should know about the pharmacological treatment of acute myocardial infarction.
    Verheugt FW
    Semin Interv Cardiol; 1999 Mar; 4(1):17-20. PubMed ID: 10406064
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of ximelagatran on ischemic events and death in patients with atrial fibrillation after acute myocardial infarction in the efficacy and safety of the oral direct thrombin inhibitor ximelagatran in patients with recent myocardial damage (ESTEEM) trial.
    Tangelder MJ; Frison L; Weaver D; Wilcox RG; Bylock A; Emanuelsson H; Held P; Oldgren J
    Am Heart J; 2008 Feb; 155(2):382-7. PubMed ID: 18215612
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Strategies to improve reperfusion with fibrinolytic therapy in ST-T elevation myocardial infarction].
    Jerjes-Sánchez C; Sosa del Angel E; García Sosa A; Reyes Cerezo E; Garza Ruiz A
    Arch Cardiol Mex; 2003; 73(1):46-58. PubMed ID: 12820494
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Thrombolytic therapy: overview of results in major vascular occlusions.
    Marder VJ
    Thromb Haemost; 1995 Jul; 74(1):101-5. PubMed ID: 8578440
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Risk factors and outcome of in-hospital ischemic stroke in patients with non-ST elevation acute coronary syndromes.
    Segev A; Strauss BH; Tan M; Buller CE; Mendelsohn AA; Langer A; Goodman SG;
    Int J Cardiol; 2008 Sep; 129(2):233-7. PubMed ID: 17976842
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Indications of anticoagulant and fibrinolytic drugs in the prevention and therapy of thromboembolic diseases].
    Verstraete M
    Clin Ter; 1975 Jun; 73(5):403-22. PubMed ID: 1139864
    [No Abstract]   [Full Text] [Related]  

  • 36. [Prescription of heparin in the acute phase of myocardial infarction: expected and observed benefits...].
    Cador R; Weber S
    Arch Mal Coeur Vaiss; 1996 Nov; 89(11 Suppl):1479-84. PubMed ID: 9092406
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Thrombolytic therapy use for acute myocardial infarction and outcome in Qatar.
    Hadi HA; Al Suwaidi J; Bener A; Khinji A; Al Binali HA
    Int J Cardiol; 2005 Jul; 102(2):249-54. PubMed ID: 15982492
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Compliance with antithrombotic prescribing guidelines for patients with atrial fibrillation--a nationwide descriptive study in Taiwan.
    Lin LJ; Cheng MH; Lee CH; Wung DC; Cheng CL; Kao Yang YH
    Clin Ther; 2008 Sep; 30(9):1726-36. PubMed ID: 18840379
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antithrombotic therapy practices in US hospitals in an era of practice guidelines.
    Tapson VF; Hyers TM; Waldo AL; Ballard DJ; Becker RC; Caprini JA; Khetan R; Wittkowsky AK; Colgan KJ; Shillington AC;
    Arch Intern Med; 2005 Jul; 165(13):1458-64. PubMed ID: 16009860
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [New agents and challenges in the antithrombotic management of arterial diseases].
    Udvardy M; Rák K
    Orv Hetil; 1997 Jan; 138(2):59-65. PubMed ID: 9064617
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.